Digital disruption in healthcare has opened the market for new products that are data-driven and patient-centered. But bringing a medical device or drug to market is very different from building other kinds of products. Added layers of regulation make it a highly complex process.
The MIT xPRO Drug and Medical Device Development: A Strategic Approach program is designed for individuals and companies that operate in the health product industry as well as those looking to enter this fast-growing industry. Having a background in health sciences is helpful, but not required. The program is ideal for:
Participants include representatives from companies like:
Participants hold job functions and titles such as:
On your journey through this program you will encounter individuals with similar interests but from various companies and job functions.
Global med-tech industry is $430 Bn with 5% growth expected annually.
Jobs related to medical product
development grew by 73% in the last year.
(Source: Emsi data)
Upon completion of the program, participants will:
Program Director and
MIT Associate Dean of Innovation
“This program explodes the notion that there is ‘research’ followed by ‘development’. These forces are intertwined until you launch it.”
Over eight weeks, including the orientation week, you will learn how to anticipate and address the complexities involved with developing medical products. Each week covers one theme, divided into specific topics.
Week 1: Strategy, Reimbursement, and Proof of Concept
Week 2: Intellectual Property, Outcome Measures, Trials and Indications
Week 3: Quality and Medical Devices
Week 4: Diagnostics, Biomarkers, and Wearable Devices
Week 5: Software, Target Selection and Drug Discovery, and Absorption, Distribution and Metabolism
Week 6: Toxicity, Formulation, and Stability
Week 7: Parenteral Products and Biologics
For full details on the program modules, please download the brochure.DOWNLOAD BROCHURE
You will play the role of a drug developer for an osteoporosis drug that has failed its clinical trial. Your task is to determine why the trial failed.
You will play the role of a Corvia quality engineer, writing a quality systems summary for your CEO that addresses the quality elements for this market bound product.
You will play the role of a Lab Manager for a pharmaceutical company whose drug form, ritonavir, has inexplicably changed, impacting the drug’s efficacy and numerous patients’ lives. Your task is to provide a causal factor analysis of why this drug has changed and a recommendation to this problem.
You will play the role of a drug developer working on a new pain relief drug. Your task is to identify the surrogate endpoints and the patient population for your Proof of Concept test to ensure your drug has its desired effects.
You will learn from industry experts from a wide variety of backgrounds, including leaders in healthcare, pharmaceuticals, venture capital, insurance, intellectual property law, and regulatory agencies. Featured experts include:
Senior Managing Partner, CEO,
Director, Center for Drug
Evaluation and Research,
PhD, President and Chief
PhD, Director of the Motion
Spaulding Rehabilitation Hospital
VP, Immunology Scientific
Innovation at Johnson &
Executive VP & CTO,
PhD, Consultant, Formerly the
VP of Global Pharmacology
Chief Scientific Officer,
3rd Rock Ventures
PhD, Clinical and Technical
President and Chief Executive
Officer, Voyager Therapeutics
PharmD, BCPS Chief
VP, Head of Worldwide Medicinal
Chemistry Pfizer (Now SVP, Medicinal Science & Technology, Glaxo Klein Smith)
PhD, Research Manager,
Surgical Innovations at Medtronic
PhD, JD Partner,
Download the program brochure for more information on the industry leaders.DOWNLOAD BROCHURE
Over 40 Interviews
with Industry Experts
Directly from MIT xPRO
Michael is the David H. Koch Professor of Engineering and a Professor of Materials Science and Engineering at the Massachusetts Institute of Technology at the David H. Koch Institute for Integrative Cancer Research. He has a B.S. in chemistry and a Ph.D. in chemical engineering from the University of California at Berkeley.
He is the faculty director of the Lemelson-MIT Program, a U.S.-based program aimed at inspiring youth to be inventive. Michael is also co-director of MIT’s Innovation Initiative and the Associate Dean of Innovation for the School of Engineering. He has also started three successful pharmaceutical and three medical device companies.
Get recognized! Upon successful completion of this program, MIT xPRO grants a certificate of completion to participants. This program is graded as a pass or fail; participants must receive 80% to pass and obtain the certificate of completion.
After successful completion of the program, your verified digital certificate will be emailed to you, at no additional cost, in the name you used when registering for the program. All certificate images are for illustrative purposes only and may be subject to change at the discretion of MIT.